SEARCH

SEARCH BY CITATION

References

  • 1
    Rubin MR, Cosman F, Lindsay R, Bilezikian JP 2002 The anabolic effects of parathyroid hormone. Osteoporos Int 13:267277.
  • 2
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:18461853.
  • 3
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Teriparatide [recombinant human parathyroid hormone (1-34)] improves both cortical and cancellous bone structure. J Bone Miner Res 18:19321941.
  • 4
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:14341441.
  • 5
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312321.
  • 6
    Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426438.
  • 7
    Tashjian AH, Chabner BA 2002 Clinical safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in postmenopausal women and men. J Bone Miner Res 17:11511161.
  • 8
    Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen CA, Reginster J-Y, Stepan JJ, Myers S, Mitlak BH 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide [recombinant human parathyroid hormone (1-34)] in postmenopausal women with osteoporosis. Arch Intern Med 164:20242030.
  • 9
    Lu Y, Ye K, Mathur A, Hui S, Fuerst T, Genant H 1997 Comparative calibration without a gold standard. Stat Med 16:18891905.
  • 10
    Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ III 1993 Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:10011005.
  • 11
    Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, de Laet C, Jonsson B 2004 Mortality after osteoporotic fractures. Osteoporos Int 15:3842.
  • 12
    Browner WS, Seeley DG, Vogt TM, Cummings SR 1991 Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 338:355358.
  • 13
    Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH 2004 Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int.
  • 14
    Hochberg M 2000 Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. Drugs Aging 17:317330.
  • 15
    National Osteoporosis Foundation 1998 Physician's guide to prevention and treatment of osteoporosis. Osteoporos Int 8:S1S88.
  • 16
    Meunier PJ, Boivin G 1997 Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications. Bone 21:373377.
  • 17
    Ejersted C, Oxlund H, Eriksen EF, Andreassen TT 1998 Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone 23:4352.
  • 18
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 15:944951.
  • 19
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925931.
  • 20
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:21292134.
  • 21
    Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP 2004 The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide. Osteoporos Int 15:992997.